AZ's durvalumab on partial clinical hold

AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA placed a partial clinical hold on trials of its PD-L1 inhibitor durvalumab ( MEDI4736) as monotherapy or in combination with tremelimumab ( CP-675) to treat squamous cell carcinoma of the head and neck (SCCHN). The hold follows the pharma's decision to pause enrollment in the Phase III KESTREL and EAGLE trials to analyze reported bleeding events.

AstraZeneca said existing patients will continue in the trials. ...